Suppr超能文献

阿达木单抗(修美乐)生物类似药HS016的物理化学及功能特性

Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).

作者信息

Gao Dong, Nie Lei, Yuan Junjie, Hu Feng, Wu Zhenhua, Lin Qunhai, Wang Haibin

机构信息

BioRay Pharmaceutical Co., Ltd., Taizhou, China.

Hisun BioPharmaceutical Co., Ltd., Hangzhou, China.

出版信息

J Pharm Sci. 2022 Apr;111(4):1142-1151. doi: 10.1016/j.xphs.2021.12.001. Epub 2021 Dec 3.

Abstract

The characterization of a biosimilar drug HS016, the reference product adalimumab (Humira), and their biosimilarities were determined using physical chemistry and functional similarity tests. The primary and higher order structures, size and charge variants, glycosylation profiles, and in vitro potency of both antibodies were characterized both for unstressed and stability samples. Slight differences were observed in the relative levels of methionine oxidation, low molecular weight components, terminal lysine variant, high mannoses and galactosylated glycans between HS016 and Humira. However, no differences in antigen binding activity, Fc receptor affinity, antibody-dependent cell-mediated cytotoxicity or complemented-dependent cytotoxicity were found. The primary and higher order structures, physicochemical properties, and biological activity of HS016 and adalimumab were similar.

摘要

使用物理化学和功能相似性测试确定了生物类似药HS016、参比产品阿达木单抗(修美乐)的特性及其生物相似性。对未处理和稳定性样品的两种抗体的一级和高级结构、大小和电荷变体、糖基化谱以及体外效力进行了表征。在HS016和修美乐之间,甲硫氨酸氧化、低分子量成分、末端赖氨酸变体、高甘露糖和半乳糖基化聚糖的相对水平存在细微差异。然而,未发现抗原结合活性、Fc受体亲和力、抗体依赖性细胞介导的细胞毒性或补体依赖性细胞毒性存在差异。HS016和阿达木单抗的一级和高级结构、物理化学性质及生物学活性相似。

相似文献

1
Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
J Pharm Sci. 2022 Apr;111(4):1142-1151. doi: 10.1016/j.xphs.2021.12.001. Epub 2021 Dec 3.
3
Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920. Epub 2018 Oct 19.
5
Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Pharmacol Res Perspect. 2020 Jun;8(3):e00604. doi: 10.1002/prp2.604.
9
The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
Ther Adv Chronic Dis. 2024 Jan 19;15:20406223231223286. doi: 10.1177/20406223231223286. eCollection 2024.
10
Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®).
Anim Cells Syst (Seoul). 2021 Jun 23;25(3):182-194. doi: 10.1080/19768354.2021.1943709. eCollection 2021.

引用本文的文献

2
Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study.
Front Pharmacol. 2023 Oct 16;14:1259183. doi: 10.3389/fphar.2023.1259183. eCollection 2023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验